Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects the nerve cells responsible for voluntary muscle movement. While there is no cure yet, early recognition, coordinated care, and access to evidence-based treatments can help maintain function and quality of life. Cape Fear Valley Health connects individuals and families with multidisciplinary expertise, practical support, and up-to-date options in care and research for amyotrophic lateral sclerosis and related ALS variants.
Most cases are sporadic, occurring without a family history. About 5–10% are familial and linked to inherited gene changes such as C9orf72, SOD1, FUS, or TARDBP. The rate of progression varies; some people experience slower changes over many years, while others decline more quickly. Clinicians sometimes describe ALS variants to capture different patterns of onset and spread within the broader spectrum of ALS disease.
ALS can occur at any adult age but is most often diagnosed between 55 and 75. Men are affected slightly more often than women early on, with the difference narrowing over time. In the United States, approximately 5,000 new cases are diagnosed each year, with an estimated prevalence of 3–5 per 100,000 people.
Symptoms of Amyotrophic Lateral Sclerosis
Early signs often include focal muscle weakness, such as a weak grip, foot drop, or frequent tripping. Muscle cramps and fasciculations (visible twitching) are common. Bulbar symptoms may appear as slurred or nasal speech, hoarseness, or difficulty swallowing. Fatigue that seems out of proportion to activity and shortness of breath with exertion or when lying flat can develop as respiratory muscles weaken, reflecting underlying ALS pathophysiology that involves both upper and lower motor pathways.
Two common patterns of onset include:
- Limb-onset ALS, which begins in an arm or leg and spreads, often presenting with weakness, cramping, and stiffness.
- Bulbar-onset ALS, which starts with speech and swallowing difficulties and may progress to limb weakness.
Over time, both patterns can involve spasticity, hyperreflexia, and muscle wasting as degeneration of ALS neuron networks advances. Recognised ALS variants also include primary lateral sclerosis and progressive muscular atrophy, which focus either on upper or lower motor systems but can intersect with ALS disease over time.
Seek prompt neurological evaluation for rapidly progressive weakness, new problems with speech or swallowing, unexplained falls, significant muscle wasting or persistent twitching, or shortness of breath at rest or during sleep. Sudden choking, frequent aspiration, or signs of nighttime hypoventilation require immediate medical attention.
Diagnosis and Testing for Amyotrophic Lateral Sclerosis
Diagnosis is based on a clinical picture that shows both upper motor neuron signs (increased reflexes, spasticity, Babinski sign) and lower motor neuron signs (atrophy, fasciculations, weakness) in multiple body regions, with progression over time. A detailed neurological exam and review of symptoms and family history guide the evaluation of suspected amyotrophic lateral sclerosis and ALS variants.
Electromyography (EMG) and nerve conduction studies assess muscle and motor nerve health and often show evidence of denervation in multiple areas. MRI of the brain and spinal cord helps exclude structural conditions that can mimic ALS disease. Blood tests evaluate for metabolic, inflammatory, or infectious causes. In select cases, cerebrospinal fluid analysis or other studies are used to rule out treatable mimics and clarify ALS pathophysiology in complex presentations.
Genetic testing may be recommended for those with a family history of ALS or frontotemporal dementia, younger-onset cases, or when results may affect treatment or clinical trial eligibility. Referral to a neuromuscular specialist or an ALS clinic is advisable whenever amyotrophic lateral sclerosis is suspected to ensure a thorough workup and timely access to multidisciplinary care.
Treatment for Amyotrophic Lateral Sclerosis
Current disease-modifying therapies can modestly slow progression in eligible patients. FDA-approved options include riluzole, edaravone (intravenous or oral), and sodium phenylbutyrate/taurursodiol. Treatment goals focus on preserving function, managing symptoms proactively, and supporting respiratory and nutritional status in the context of ALS disease.
Multidisciplinary care improves outcomes. Team members may include:
- Physical therapy for mobility, stretching, and fall prevention.
- Occupational therapy for energy conservation, adaptive techniques, and home modifications.
- Speech-language pathology for speech, swallowing, and communication strategies.
- Respiratory therapy to monitor breathing, guide noninvasive ventilation, and support airway clearance.
- Dietitians to optimize nutrition and weight maintenance, including discussion of feeding tube placement when appropriate.
Symptom control is central to care. Medications may help with spasticity (such as baclofen or tizanidine), muscle cramps, excessive saliva (anticholinergics or botulinum toxin), pseudobulbar affect, mood disorders, sleep disturbance, and pain. Early conversations about advance care planning clarify preferences for ventilation, feeding tubes, and emergency interventions. Palliative care should be integrated early to manage symptoms, support decision-making, and enhance quality of life throughout the illness of amyotrophic lateral sclerosis.
